Finally, we demonstrate a correlation between NFκB activation, IL-6 expression and cervical disease progression, suggesting that targeting the IL-6 pathway to prevent STAT3 activation may have therapeutic benefits in cervical cancer. This evidence concerns the gene IL6 and cervical carcinoma.